SEARCH

SEARCH BY CITATION

References

  • 1
    Mears JM & Kaplan B. Proton pump inhibitors: new drugs and indications. Am Fam Physician 1996; 53: 285 92.
  • 2
    Schulman MI & Orlando RC. Treatment of gastroesophageal reflux: the role of proton pump inhibitors. Adv Int Med 1995; 40: 273 302.
  • 3
    Fujisaki H, Shibata H, Oketani K, et al. Inhibition of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991; 42: 321 8.
  • 4
    Morii M, Hamatani K, Takeguchi N. The proton pump inhibitor, E3810, binds to the N-terminal half of the α-subunit of gastric H+, K+-ATPase. Biochem Pharmacol 1995; 49: 1729 34.
  • 5
    Cloud ML, Enas N, Humphries TJ, Bassion S, the Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose–response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 1998; 43: 993 1000.
  • 6
    Wallmark B. Omeprazole: mode of action and effect on acid secretion in animals. Scand J Gastroenterol 1989; 24 (Suppl. 166): 12 8.
  • 7
    Maton PN. Omeprazole. N Engl J Med 1991; 324: 965 75.
  • 8
    Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225 50.
  • 9
    O’Connor HJ. The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol 1994; 29 (Suppl. 201): 11 5.
  • 10
    Park J-B, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996; 19: 182 7.
  • 11
    Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490 6.
  • 12
    Hirai M, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995; 30: 461 4.
  • 13
    Bayerdorffer E, Mannes GA, Sommer A, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 697 702.
  • 14
    Labenz J, Gyenes E, Ruhl GH, Borsch G. Short term therapy with high dose omeprazole and amoxicillin for eradication of Helicobacter pylori. Ital J Gastroenterology 1991; 23 (Suppl. 2): 109.
  • 15
    Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998; 93: 1909 13.
    Direct Link:
  • 16
    European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8 13.
  • 17
    Omeprazole. In: Physicians’ Desk Reference, 53rd edn. Medical Economics Company, Inc., Montvale, NJ, 1999: 584 7.
  • 18
    Lichtenberger LM, Delansorne R, Graziani LA. Importance of amino acid uptake and decarboxylation in gastrin release from isolated G cells. Nature 1982; 295: 698 700.
  • 19
    Walsh JH, Richardson CT, Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest 1975; 55: 462 8.
  • 20
    Freston JW, Borch K, Brand SJ, et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells: a review and analysis. Dig Dis Sci 1995; 40 (Suppl.): 50S 62S.
  • 21
    Karnes WE & Walsh JH. The gastrin hypothesis. Implications for antisecretory drug selection. J Clin Gastroenterol 1990; 12 (Suppl. 2): S7 12.
  • 22
    Blanshard C, Millson C, Sercombe J, Pounder RE. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996; 39 (Suppl. 3): A47 8 (Abstract).
  • 23
    Humphries T, Dekkers C, Beker J, et al. Magnitude of changes in fasting serum gastrin in 211 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year. Am J Gastroenterol 1998; 93: 1637 (Abstract).
  • 24
    Birbara C, Breiter J, Collins D, et al. Rabeprazole: preventing endoscopic and symptomatic relapse in erosive or ulcerative GERD. Am J Gastroenterol 1998; 93: 1630 (Abstract).
  • 25
    Caos A, Moskovitz M, Perdomo C, Niecestro R, Hahne W. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology 1999; 116: A132 (Abstract).
  • 26
    Hakanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F. Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul Pept 1986; 13: 225 33.
  • 27
    Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 (Suppl. 1): 42 55.
  • 28
    Borch K. Atrophic gastritis and gastric carcinoid tumors. Ann Med 1989; 21: 291 7.
  • 29
    Creutzfeldt W, Stockmann F, Conlon JM, Folsch UR, Bonatz G, Wulfrath M. Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion 1986; 35 (Suppl. 1): 84 97.
  • 30
    Arnold R. Safety of proton pump inhibitors–an overview. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 65 70.
  • 31
    Rindi G, Fiocca R, Humphries T. Argyrophil ECL histology in the gastric corpus and antrum in 243 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year. Digestion 1998; 59 (Suppl. 3): 234 (Abstract).
  • 32
    Thorburn CM, Friedman GD, Orentreich N, Vogelman JH, Parsonnet J. High gastrin levels increase risk for colorectal carcinoma. Gastroenterology 1996; 110: A603 (Abstract).
  • 33
    Smith JP, Wood JG, Solomon TE. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 1989; 34: 171 4.
  • 34
    Seitz J-F, Giovanni M, Gourvenet J, Gauthier AP. Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol 1991; 13: 541 5.
  • 35
    Suzuki H, Matsumoto K, Terashima H. Serum levels of gastrin in patients with colorectal neoplasia. Dis Colon Rectum 1988; 31: 716 7.
  • 36
    Creutzfeldt W & Lamberts R. Is hypergastrinaemia dangerous to man? Scand J Gastroenterol 1991; 26 (Suppl. 180): 179 91.
  • 37
    Graffner H, Singh G, Chaudry I, Milsom JW. Omeprazole-induced hypergastrinemia does not influence growth of colon carcinoma. Dig Dis Sci 1992; 37: 485 9.
  • 38
    Powers RE, Lawton GP, Modlin IM. Genotoxicity, carcinogenicity and acid suppressing medications. Pharmacol Ther 1995; 65: 303 17.
  • 39
    Burlinson B, Morriss S, Gatehouse DG, Tweats DJ, Jackson MR. Uptake of tritiated thymidine by cells of the rat gastric mucosa after exposure to loxtidine or omeprazole. Mutagenesis 1991; 6: 11 8.
  • 40
    Holt S, Zhao-Hua Z, Powers RE. Observations on a proposed measure of genotoxicity in rat gastric mucosa. Gastroenterology 1991; 101: 650 6.
  • 41
    Dammann HG, Burkhardt F, Bell NE, Bjaaland T. Rabeprazole does not affect endocrine function in healthy subjects. Am J Gastroenterol 1996; 91: 1909 (Abstract).
  • 42
    Santucci L, Farroni F, Fiorucci S, Morelli A. Gynecomastia during omeprazole therapy. N Engl J Med 1991; 324: 635 (Letter).